COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
06/05/2026
Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Modulation Therapy (“ [...]
Cannara Completes Acquisition of Medican Organic Inc.
06/05/2026
MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara complète l’acquisition de Medican Organic Inc.
06/05/2026
MONTRÉAL, 06 mai 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de qualité supérieure [...]
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
06/05/2026
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved $21.7 million in [...]
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
06/05/2026
200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a [...]
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
06/05/2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - [...]
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
06/05/2026
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its [...]
Glass House Brands Announces Application for DEA Registration of Certain Medical Operations
06/05/2026
LONG BEACH, Calif. and TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) today announced that it has submitted [...]
Cronos Expands Pre-Roll Portfolio with Spinach STIX®
06/05/2026
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, announced today that Spinach STIX ® , its latest innovation in its popular line- [...]
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
06/05/2026
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell’s next generation personalized immunotherapy [...]
Bioventus Reports First Quarter Financial Results
06/05/2026
Q1 reported revenue of $132.1 million increased 7% First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted share Non-GAAP earnings* of $0.15 per diluted share [...]
Medline Reports First Quarter 2026 Results
06/05/2026
Net sales of $7.4 billion, an increase of 10.7% Net income of $239 million, a decrease of 25.8% Adjusted EBITDA 1 of $776 million, a decrease of 10.6% Raising full year 2026 Organic Sales 2 guidance range to 8.5% to 9.5 [...]
Crescent Biopharma to Present at May Investor Conferences
06/05/2026
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
06/05/2026
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will [...]
Immusoft to Present Data Highlighting Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial at ASGCT 2026
06/05/2026
SAN FRANCISCO, May 06, 2026 (GLOBE NEWSWIRE) -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that Scott McIvor, Chief Development Officer at Immusoft, [...]
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update
06/05/2026
-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at 8:00am ET CHASKA, [...]
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
06/05/2026
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quarter of 2026 Initiation [...]
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary
06/05/2026
Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6 th May 2026 Immutrin Ltd, (“Immutrin” [...]

Pages